Skip to main content
ArticleOPEN ACCESS

To respond or not to respond to CD40 agonism: That is the prediction

OncoImmunology
DOI: 10.4161/onci.1.1.17827
3Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In the context of the clinical development of a CD40-stimulatory monoclonal antibody for the treatment of B-cell cancers, a tumor mRNA-based gene signature reflecting CD40 signaling pathway activation status was identified that could be used to predict responding and non-responding patients with diffuse large B cell lymphoma (DLBCL). © 2012 Landes Bioscience.

Cite

CITATION STYLE

APA

Shi, X., & Dornan, D. (2012). To respond or not to respond to CD40 agonism: That is the prediction. OncoImmunology. https://doi.org/10.4161/onci.1.1.17827

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free